Prostate Cancer

Even though Prostate Cancer (PCa) remains the most frequently diagnosed cancer type in men (estimated to be the fifth leading cause of cancer related deaths in men worldwide), death rates for prostate cancer have been decreasing in many countries. In surgical treatment, incomplete resection of PCa and understaging of possible undetected metastases may lead to disease recurrence and consequently poor patient outcome. Curative options are indicated. One of these curative options is surgical removal of all cancerous tissue. Depending on the extent of the disease, surgery may be combined with Adjuvant Radiotherapy, hormone therapy and chemotherapy. To increase the chance of accurate staging and subsequently complete removal of all cancerous tissue, prostate specific membrane antigen (PSMA) targeting agents may provide the surgeon an aid for the intraoperative detection and removal of PCa lesions.

Sources: NIH.gov, ACS journals